New hope for tough lymphoma: first human trial of ABBV 291 launches
NCT ID NCT06667687
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 26 times
Summary
This early-stage study tests an experimental drug called ABBV 291 in adults with Non-Hodgkin's lymphoma that has returned or stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 165 participants worldwide will receive the drug through an IV, and researchers will monitor side effects and disease changes closely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN'S LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aichi Cancer Center /ID# 267471
RECRUITINGNagoya, Aichi-ken, 464-8681, Japan
-
Carolina BioOncology Institute /ID# 265259
COMPLETEDHuntersville, North Carolina, 28078, United States
-
Hadassah Medical Center-Hebrew University /ID# 261658
RECRUITINGJerusalem, Jerusalem, 91120, Israel
-
National Cancer Center Hospital East /ID# 261775
RECRUITINGKashiwa-shi, Chiba, 277-8577, Japan
-
START Mountain Region /ID# 267592
COMPLETEDWest Valley City, Utah, 84119-3602, United States
-
Sir Charles Gairdner Hospital /ID# 268579
RECRUITINGNedlands, Western Australia, 6009, Australia
-
St Vincent's Hospital Melbourne /ID# 261664
RECRUITINGFitzroy Melbourne, Victoria, 3065, Australia
-
Tel Aviv Sourasky Medical Center /ID# 261659
RECRUITINGTel Aviv, Tel Aviv, 6423906, Israel
-
Texas Oncology - Central/South Texas /ID# 270946
RECRUITINGAustin, Texas, 78705, United States
-
The Cancer Institute Hospital Of JFCR /ID# 267470
RECRUITINGKoto-ku, Tokyo, 135-8550, Japan
-
The Christie /ID# 267177
RECRUITINGManchester, M20 4BX, United Kingdom
-
University Hospitals Plymouth NHS Trust /ID# 267174
RECRUITINGPlymouth, PL6 5FP, United Kingdom
-
Virginia Cancer Specialists - Fairfax /ID# 265082
COMPLETEDFairfax, Virginia, 22031, United States
-
Willamette Valley Cancer Institute and Research Center /ID# 270945
RECRUITINGEugene, Oregon, 97401, United States
Conditions
Explore the condition pages connected to this study.